PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
90.50%
EBIT growth above 1.5x TRVN's 9.64%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
74.50%
Operating income growth above 1.5x TRVN's 9.64%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
91.74%
Net income growth above 1.5x TRVN's 7.40%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
91.71%
EPS growth above 1.5x TRVN's 7.42%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
91.71%
Diluted EPS growth above 1.5x TRVN's 7.42%. David Dodd would see if there's a robust moat protecting these shareholder gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
55.51%
OCF growth above 1.5x TRVN's 20.82%. David Dodd would confirm a clear edge in underlying cash generation.
55.51%
FCF growth above 1.5x TRVN's 16.24%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-103253.49%
Negative 10Y OCF/share CAGR while TRVN stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-39279.54%
Negative 5Y OCF/share CAGR while TRVN is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-22130.85%
Negative 3Y OCF/share CAGR while TRVN stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-247692.89%
Negative 10Y net income/share CAGR while TRVN is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-3218.28%
Negative 5Y net income/share CAGR while TRVN is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-4231.04%
Negative 3Y CAGR while TRVN is 0.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
4781.98%
Equity/share CAGR of 4781.98% while TRVN is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
636.42%
Equity/share CAGR of 636.42% while TRVN is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
374.63%
Equity/share CAGR of 374.63% while TRVN is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-42.01%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-51.92%
We have a declining book value while TRVN shows 100.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-46.67%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-6.56%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-79.23%
We cut SG&A while TRVN invests at 18.44%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.